A unique dosage form to evaluate the mechanical destructive force in the gastrointestinal tract

The purpose of this study was to prepare tablets that could evaluate the destructive force in the gastrointestinal (GI) tract. Many factors are known to affect in vivo drug release from oral dosage forms. There is still relatively little information on the mechanical destructive force in the GI trac...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of pharmaceutics Vol. 208; no. 1; pp. 61 - 70
Main Authors Kamba, Masaharu, Seta, Yasuo, Kusai, Akira, Ikeda, Masaru, Nishimura, Kenji
Format Journal Article
LanguageEnglish
Published Amsterdam Elsevier B.V 04.11.2000
Elsevier
Subjects
Online AccessGet full text
ISSN0378-5173
1873-3476
DOI10.1016/S0378-5173(00)00552-4

Cover

Loading…
Abstract The purpose of this study was to prepare tablets that could evaluate the destructive force in the gastrointestinal (GI) tract. Many factors are known to affect in vivo drug release from oral dosage forms. There is still relatively little information on the mechanical destructive force in the GI tract. Press-coated tablets with an extremely brittle outer layer were developed using a unique, highly hydrophobic Teflon powder that could be shaped with weak compression force. A marker drug contained in the tablets was released only when the tablets received a force larger than its predetermined crushing strength. We referred to this type of tablet as a ‘destructive force dependent release system’ (DDRS). A total of nine healthy, male subjects were orally administered the tablets under fed and/or fasting conditions. Tablets with a predetermined crushing strength of 1.50 N were crushed by all of the four subjects who took them under fed conditions and two of the five subjects under fasting conditions. Tablets with a crushing strength of 1.89 N were crushed by two of the six subjects who took them under fed conditions and none of the five subjects under fasting conditions. The range of mechanical destructive force in the human stomach was obtained.
AbstractList The purpose of this study was to prepare tablets that could evaluate the destructive force in the gastrointestinal (GI) tract. Many factors are known to affect in vivo drug release from oral dosage forms. There is still relatively little information on the mechanical destructive force in the GI tract. Press-coated tablets with an extremely brittle outer layer were developed using a unique, highly hydrophobic Teflon powder that could be shaped with weak compression force. A marker drug contained in the tablets was released only when the tablets received a force larger than its predetermined crushing strength. We referred to this type of tablet as a 'destructive force dependent release system' (DDRS). A total of nine healthy, male subjects were orally administered the tablets under fed and/or fasting conditions. Tablets with a predetermined crushing strength of 1.50 N were crushed by all of the four subjects who took them under fed conditions and two of the five subjects under fasting conditions. Tablets with a crushing strength of 1.89 N were crushed by two of the six subjects who took them under fed conditions and none of the five subjects under fasting conditions. The range of mechanical destructive force in the human stomach was obtained.The purpose of this study was to prepare tablets that could evaluate the destructive force in the gastrointestinal (GI) tract. Many factors are known to affect in vivo drug release from oral dosage forms. There is still relatively little information on the mechanical destructive force in the GI tract. Press-coated tablets with an extremely brittle outer layer were developed using a unique, highly hydrophobic Teflon powder that could be shaped with weak compression force. A marker drug contained in the tablets was released only when the tablets received a force larger than its predetermined crushing strength. We referred to this type of tablet as a 'destructive force dependent release system' (DDRS). A total of nine healthy, male subjects were orally administered the tablets under fed and/or fasting conditions. Tablets with a predetermined crushing strength of 1.50 N were crushed by all of the four subjects who took them under fed conditions and two of the five subjects under fasting conditions. Tablets with a crushing strength of 1.89 N were crushed by two of the six subjects who took them under fed conditions and none of the five subjects under fasting conditions. The range of mechanical destructive force in the human stomach was obtained.
The purpose of this study was to prepare tablets that could evaluate the destructive force in the gastrointestinal (GI) tract. Many factors are known to affect in vivo drug release from oral dosage forms. There is still relatively little information on the mechanical destructive force in the GI tract. Press-coated tablets with an extremely brittle outer layer were developed using a unique, highly hydrophobic Teflon powder that could be shaped with weak compression force. A marker drug contained in the tablets was released only when the tablets received a force larger than its predetermined crushing strength. We referred to this type of tablet as a 'destructive force dependent release system' (DDRS). A total of nine healthy, male subjects were orally administered the tablets under fed and/or fasting conditions. Tablets with a predetermined crushing strength of 1.50 N were crushed by all of the four subjects who took them under fed conditions and two of the five subjects under fasting conditions. Tablets with a crushing strength of 1.89 N were crushed by two of the six subjects who took them under fed conditions and none of the five subjects under fasting conditions. The range of mechanical destructive force in the human stomach was obtained.
Author Kusai, Akira
Ikeda, Masaru
Nishimura, Kenji
Kamba, Masaharu
Seta, Yasuo
Author_xml – sequence: 1
  givenname: Masaharu
  surname: Kamba
  fullname: Kamba, Masaharu
  email: kmash@shina.sankyo.co.jp
  organization: Product Development Laboratories, Sankyo Co., Ltd, 2-58, 1-chome, Hiromachi, Shinagawa-ku, Tokyo 140, Japan
– sequence: 2
  givenname: Yasuo
  surname: Seta
  fullname: Seta, Yasuo
  organization: Product Development Laboratories, Sankyo Co., Ltd, 2-58, 1-chome, Hiromachi, Shinagawa-ku, Tokyo 140, Japan
– sequence: 3
  givenname: Akira
  surname: Kusai
  fullname: Kusai, Akira
  organization: Product Development Laboratories, Sankyo Co., Ltd, 2-58, 1-chome, Hiromachi, Shinagawa-ku, Tokyo 140, Japan
– sequence: 4
  givenname: Masaru
  surname: Ikeda
  fullname: Ikeda, Masaru
  organization: Product Development Laboratories, Sankyo Co., Ltd, 2-58, 1-chome, Hiromachi, Shinagawa-ku, Tokyo 140, Japan
– sequence: 5
  givenname: Kenji
  surname: Nishimura
  fullname: Nishimura, Kenji
  organization: Drug Metabolism and Pharmacokinetics Research Laboratories, Sankyo Co. Ltd, 2-58, 1-chome, Hiromachi, Shinagawa-ku, Tokyo 140, Japan
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1523101$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/11064212$$D View this record in MEDLINE/PubMed
BookMark eNqFkUtvFDEQhC0URDaBnwCaA0LhMNC2x_NQDiiKwkOKxAE4W552T2I0YwfbsxL_Hmd3CRKXnPrQX1Wruk7YkQ-eGHvJ4R0H3r7_BrLra8U7eQbwFkApUTdP2Ib3naxl07VHbPOAHLOTlH4CQCu4fMaOOYe2EVxsmL6oVu9-rVTZkMwNVVOIS5VDRVszryZTlW-pWghvjXdo5spSynHF7LY7FqlyfsfcmLIIzucCOF_IHA3m5-zpZOZELw7zlP34ePX98nN9_fXTl8uL6xrlALkeANuu61urJmzlJJXCYRxQdJNVEix2g-G2pd4KI5sBoSQT40QNDDSOUpA8ZW_2vncxlDQp68UlpHk2nsKadCfKHaH6Ar46gOu4kNV30S0m_tZ_X1KA1wfApBJ4isajS_84JWQpoGDnewxjSCnSpNFlk13wJbebNQd935Pe9aTvS9AAeteTbopa_ad-8H9E92Gvo_LLraOoEzrySNZFwqxtcI84_AF2P6ok
CODEN IJPHDE
CitedBy_id crossref_primary_10_1111_ijfs_16927
crossref_primary_10_3897_pharmacia_70_e111731
crossref_primary_10_1111_j_1750_3841_2008_00766_x
crossref_primary_10_1146_annurev_food_030713_092315
crossref_primary_10_1016_j_ijpharm_2013_08_077
crossref_primary_10_1021_acsbiomaterials_8b01040
crossref_primary_10_1016_j_foodres_2023_112810
crossref_primary_10_1248_bpb_26_1442
crossref_primary_10_3109_1061186X_2010_504264
crossref_primary_10_1248_cpb_56_792
crossref_primary_10_1016_j_ejpb_2019_01_026
crossref_primary_10_1016_S0939_6411_03_00136_X
crossref_primary_10_1007_s13346_021_00905_w
crossref_primary_10_1016_j_ejps_2009_06_010
crossref_primary_10_1016_j_ijpharm_2016_10_069
crossref_primary_10_1111_j_1750_3841_2010_01856_x
crossref_primary_10_1248_cpb_55_1574
crossref_primary_10_3136_nskkk_65_543
crossref_primary_10_1016_j_ejpb_2013_12_008
crossref_primary_10_1016_j_jfoodeng_2019_07_021
crossref_primary_10_1208_s12249_013_0050_2
crossref_primary_10_1039_C4FO00041B
crossref_primary_10_1016_j_ejpb_2007_03_002
crossref_primary_10_1208_s12249_014_0246_0
crossref_primary_10_1016_j_foodres_2019_04_015
crossref_primary_10_1208_s12249_018_1022_3
crossref_primary_10_1016_j_asej_2021_02_033
crossref_primary_10_1016_j_ijpharm_2004_11_011
crossref_primary_10_1002_jps_21499
crossref_primary_10_1016_j_foodres_2016_10_049
crossref_primary_10_1016_j_ijpharm_2019_118865
crossref_primary_10_1016_j_ejpb_2010_10_005
crossref_primary_10_1016_j_ijpharm_2013_04_034
crossref_primary_10_1016_j_ijpharm_2013_12_003
crossref_primary_10_1080_10408398_2019_1707770
crossref_primary_10_1016_S0169_409X_01_00184_3
crossref_primary_10_1021_mp100149j
crossref_primary_10_1016_j_xphs_2018_10_051
crossref_primary_10_1002_jps_24511
crossref_primary_10_1016_j_ejps_2014_02_010
crossref_primary_10_1016_j_foodres_2013_11_017
crossref_primary_10_1016_j_ijpharm_2013_11_062
crossref_primary_10_1016_j_ejpb_2020_11_023
crossref_primary_10_1073_pnas_1002292107
crossref_primary_10_1016_j_addr_2021_113925
crossref_primary_10_1016_j_biomaterials_2010_01_045
crossref_primary_10_1208_s12249_011_9689_8
crossref_primary_10_1016_S0378_5173_01_00844_4
crossref_primary_10_1016_j_jddst_2024_105563
crossref_primary_10_1080_03639040801926683
crossref_primary_10_1208_s12249_014_0225_5
crossref_primary_10_3109_10837450_2013_823990
crossref_primary_10_3109_03639045_2011_645836
crossref_primary_10_1109_JSEN_2016_2627798
crossref_primary_10_1007_s11095_007_9462_6
crossref_primary_10_1016_j_ijpharm_2008_08_016
crossref_primary_10_1557_adv_2019_370
crossref_primary_10_7243_2050_120X_1_1
crossref_primary_10_1208_s12249_017_0825_y
crossref_primary_10_1517_17425247_2011_592828
crossref_primary_10_1016_j_ces_2014_04_006
crossref_primary_10_1557_s43579_021_00024_0
crossref_primary_10_1007_s11095_005_5272_x
crossref_primary_10_3109_03639040903311081
crossref_primary_10_1016_j_ejpb_2016_10_027
crossref_primary_10_1080_09205063_2012_703950
crossref_primary_10_1016_j_foodhyd_2020_106166
crossref_primary_10_1021_mp300604u
crossref_primary_10_1016_j_addr_2021_113943
crossref_primary_10_1016_j_foodres_2020_109296
crossref_primary_10_1016_j_ijpharm_2011_12_034
crossref_primary_10_1039_C4FO00700J
crossref_primary_10_1016_S0939_6411_01_00222_3
crossref_primary_10_1016_j_jddst_2019_101338
crossref_primary_10_1557_s43580_021_00196_w
crossref_primary_10_3390_pharmaceutics11060271
crossref_primary_10_1517_17425247_2010_527943
crossref_primary_10_1016_j_ijpharm_2018_04_005
crossref_primary_10_1007_s11094_022_02786_w
crossref_primary_10_1016_j_foodres_2020_109782
crossref_primary_10_1016_S0378_5173_02_00535_5
crossref_primary_10_1016_j_jddst_2020_102034
crossref_primary_10_1111_j_2042_7158_2012_01477_x
crossref_primary_10_1016_j_device_2023_100055
crossref_primary_10_1248_cpb_56_1234
crossref_primary_10_1016_j_ejps_2016_08_060
crossref_primary_10_1016_j_foodres_2022_111837
crossref_primary_10_1016_S0378_5173_02_00043_1
crossref_primary_10_1039_D0FO01981J
crossref_primary_10_1016_j_foodres_2016_02_019
crossref_primary_10_1016_S0168_3659_03_00203_7
crossref_primary_10_1186_1476_511X_10_51
crossref_primary_10_1016_j_ejpb_2004_02_003
crossref_primary_10_6090_jarq_51_17
crossref_primary_10_1080_03639045_2017_1323910
crossref_primary_10_1016_j_ijpharm_2015_02_040
crossref_primary_10_1016_j_jtbi_2023_111418
crossref_primary_10_1208_s12248_021_00590_0
crossref_primary_10_2165_00063030_200822040_00002
crossref_primary_10_1016_j_ijpharm_2005_12_037
crossref_primary_10_1208_s12249_011_9608_z
crossref_primary_10_1016_j_ejpb_2014_07_009
crossref_primary_10_1016_j_eurpolymj_2015_12_029
Cites_doi 10.1248/bpb1978.7.656
10.1016/S0016-5085(19)32458-8
10.1023/A:1015855829864
10.1111/j.1365-2125.1986.tb02937.x
10.1016/0378-5173(94)90356-5
10.1023/A:1015987016003
10.1002/jps.2600750313
10.1002/jps.2600550305
10.1023/A:1016231010301
10.1023/A:1015894626403
10.1002/jps.2600630136
10.1111/j.2042-7158.1988.tb05220.x
10.1016/0378-5173(96)04489-4
10.1136/gut.27.8.886
10.1016/S0016-5085(79)80182-1
10.1023/A:1016270701021
10.1136/gut.24.9.790
ContentType Journal Article
Copyright 2000 Elsevier Science B.V.
2000 INIST-CNRS
Copyright_xml – notice: 2000 Elsevier Science B.V.
– notice: 2000 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/S0378-5173(00)00552-4
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-3476
EndPage 70
ExternalDocumentID 11064212
1523101
10_1016_S0378_5173_00_00552_4
S0378517300005524
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
--M
.GJ
.~1
0R~
1B1
1RT
1~.
1~5
29J
3O-
4.4
457
4G.
53G
5GY
5VS
7-5
71M
8P~
9JM
AABNK
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATCM
AAXUO
ABFNM
ABFRF
ABJNI
ABMAC
ABOCM
ABXDB
ABYKQ
ABZDS
ACDAQ
ACGFO
ACGFS
ACIUM
ACRLP
ADBBV
ADEZE
ADMUD
AEBSH
AEFWE
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AGHFR
AGUBO
AGYEJ
AHHHB
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
C45
CS3
DU5
EBS
EFJIC
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HMT
HVGLF
HZ~
IHE
J1W
KOM
M34
M41
MO0
N9A
O-L
O9-
OAUVE
OGGZJ
OVD
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SCC
SDF
SDG
SDP
SES
SEW
SPCBC
SPT
SSP
SSZ
T5K
TEORI
WUQ
ZXP
~02
~G-
AATTM
AAXKI
AAYWO
AAYXX
ABWVN
ACRPL
ACVFH
ADCNI
ADNMO
AEIPS
AEUPX
AFJKZ
AFPUW
AGCQF
AGQPQ
AGRNS
AIGII
AIIUN
AKBMS
AKRWK
AKYEP
ANKPU
APXCP
BNPGV
CITATION
SSH
EFKBS
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c390t-90c67786d5fc63f355c9b9c27fd530dc79a1d6e8d2a349c00372bfe409ebb32e3
IEDL.DBID AIKHN
ISSN 0378-5173
IngestDate Fri Jul 11 06:16:40 EDT 2025
Wed Feb 19 02:36:11 EST 2025
Mon Jul 21 09:16:12 EDT 2025
Thu Apr 24 23:04:45 EDT 2025
Tue Jul 01 04:15:26 EDT 2025
Fri Feb 23 02:29:29 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Teflon
Gastrointestinal transit
Riboflavin
Stomach
Destructive force
Structure stability
Disintegration
Hydrophobicity
Powder compact
Release
Physical structure
Human
Urine
Pharmaceutical technology
Healthy subject
Digestive system
Oral administration
Mechanical properties
Direct compression
Dissolution
In vitro
Pressure
Physical properties
In vivo
Destructive test
Dosage form
Pharmacokinetics
Physicochemical properties
Language English
License https://www.elsevier.com/tdm/userlicense/1.0
CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c390t-90c67786d5fc63f355c9b9c27fd530dc79a1d6e8d2a349c00372bfe409ebb32e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 11064212
PQID 72390258
PQPubID 23479
PageCount 10
ParticipantIDs proquest_miscellaneous_72390258
pubmed_primary_11064212
pascalfrancis_primary_1523101
crossref_citationtrail_10_1016_S0378_5173_00_00552_4
crossref_primary_10_1016_S0378_5173_00_00552_4
elsevier_sciencedirect_doi_10_1016_S0378_5173_00_00552_4
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2000-11-04
PublicationDateYYYYMMDD 2000-11-04
PublicationDate_xml – month: 11
  year: 2000
  text: 2000-11-04
  day: 04
PublicationDecade 2000
PublicationPlace Amsterdam
PublicationPlace_xml – name: Amsterdam
– name: Netherlands
PublicationTitle International journal of pharmaceutics
PublicationTitleAlternate Int J Pharm
PublicationYear 2000
Publisher Elsevier B.V
Elsevier
Publisher_xml – name: Elsevier B.V
– name: Elsevier
References Davis, Norring-Christensen, Khosla, Feely (BIB4) 1988; 40
Chan, Mojaverian, Ziehmer, John (BIB1) 1990; 7
Levy, Jusko (BIB8) 1966; 55
Shameem, Katori, Aoyagi, Kojima (BIB13) 1995; 12
Ogata, Aoyagi, Kaniwa, Ejima, Suzuki, Ishioka, Morishita, Ohta, Takagishi, Doi, Ogura (BIB12) 1984; 7
Meyer, Thompson, Cohen (BIB10) 1979; 76
Steffensen, Pedersen (BIB15) 1986; 22
Coupe, Davis, Evans, Wilding (BIB2) 1991; 8
Stemper, Cooke (BIB16) 1975; 69
Ferrari, Bertoni, Bonferoni, Rossi, Caramella, Nyström (BIB5) 1996; 136
Stanghellini, Malagelada (BIB14) 1983; 24
Kenyon, Cole, Wilding (BIB7) 1994; 112
Lui, Amidon, Berardi, Fleischer, Youngberg, Dressman (BIB9) 1986; 75
Katori, Aoyagi, Terao (BIB6) 1995; 12
Mojaverian, Reynolds, Ouyang, Wirth, Kellner, Vlasses (BIB11) 1991; 8
Wan, Lee (BIB17) 1974; 63
Davis, Hardy, Fara (BIB3) 1986; 27
Ogata (10.1016/S0378-5173(00)00552-4_BIB12) 1984; 7
Mojaverian (10.1016/S0378-5173(00)00552-4_BIB11) 1991; 8
Ferrari (10.1016/S0378-5173(00)00552-4_BIB5) 1996; 136
Meyer (10.1016/S0378-5173(00)00552-4_BIB10) 1979; 76
Shameem (10.1016/S0378-5173(00)00552-4_BIB13) 1995; 12
Kenyon (10.1016/S0378-5173(00)00552-4_BIB7) 1994; 112
Stemper (10.1016/S0378-5173(00)00552-4_BIB16) 1975; 69
Levy (10.1016/S0378-5173(00)00552-4_BIB8) 1966; 55
Stanghellini (10.1016/S0378-5173(00)00552-4_BIB14) 1983; 24
Steffensen (10.1016/S0378-5173(00)00552-4_BIB15) 1986; 22
Davis (10.1016/S0378-5173(00)00552-4_BIB4) 1988; 40
Wan (10.1016/S0378-5173(00)00552-4_BIB17) 1974; 63
Coupe (10.1016/S0378-5173(00)00552-4_BIB2) 1991; 8
Chan (10.1016/S0378-5173(00)00552-4_BIB1) 1990; 7
Lui (10.1016/S0378-5173(00)00552-4_BIB9) 1986; 75
Davis (10.1016/S0378-5173(00)00552-4_BIB3) 1986; 27
Katori (10.1016/S0378-5173(00)00552-4_BIB6) 1995; 12
References_xml – volume: 12
  start-page: 237
  year: 1995
  end-page: 243
  ident: BIB6
  article-title: Estimation of agitation intensity in the GI tract in humans and dogs based on in vitro/in vivo correlation
  publication-title: Pharm. Res.
– volume: 76
  start-page: 801
  year: 1979
  end-page: 813
  ident: BIB10
  article-title: Sieving of solid food by the canine stomach and sieving after gastric surgery
  publication-title: Gastroenterology
– volume: 112
  start-page: 207
  year: 1994
  end-page: 213
  ident: BIB7
  article-title: The effect of food on the in vivo behaviour of enteric coated starch capsules
  publication-title: Int. J. Pharm.
– volume: 8
  start-page: 1281
  year: 1991
  end-page: 1285
  ident: BIB2
  article-title: Correlation of the gastric emptying of non-disintegrating tablets with gastrointestinal motility
  publication-title: Pharm. Res.
– volume: 55
  start-page: 285
  year: 1966
  end-page: 289
  ident: BIB8
  article-title: Factors affecting the absorption of riboflavin in man
  publication-title: J. Pharm. Sci.
– volume: 12
  start-page: 1049
  year: 1995
  end-page: 1054
  ident: BIB13
  article-title: Oral solid controlled release dosage forms: role of GI-mechanical destructive forces and colonic release in drug absorption under fasting and fed conditions in humans
  publication-title: Pharm. Res.
– volume: 24
  start-page: 790
  year: 1983
  end-page: 797
  ident: BIB14
  article-title: Gastric manometric abnormalities in patients with dyspeptic symptoms after fundoplication
  publication-title: Gut
– volume: 8
  start-page: 97
  year: 1991
  end-page: 100
  ident: BIB11
  article-title: Mechanism of gastric emptying of a non-disintegrating radiotelemetry capsule in man
  publication-title: Pharm. Res.
– volume: 69
  start-page: 649
  year: 1975
  end-page: 653
  ident: BIB16
  article-title: Gastric emptying and its relationship to antral contractile activity
  publication-title: Gastroenterogy
– volume: 27
  start-page: 886
  year: 1986
  end-page: 892
  ident: BIB3
  article-title: Transit of pharmaceutical dosage forms through the small intestine
  publication-title: Gut
– volume: 40
  start-page: 205
  year: 1988
  end-page: 207
  ident: BIB4
  article-title: Gastric emptying of large single unit dosage forms
  publication-title: J. Pharm. Pharmacol.
– volume: 22
  start-page: 571
  year: 1986
  end-page: 577
  ident: BIB15
  article-title: Food induced changes in theophylline absorption from a once a day theophylline project
  publication-title: Br. J. Clin. Pharmac.
– volume: 7
  start-page: 656
  year: 1984
  end-page: 664
  ident: BIB12
  article-title: Development and evaluation of a new peroral test agent GA-test for assessment of gastric acidity
  publication-title: J. Pharm. Dyn.
– volume: 136
  start-page: 71
  year: 1996
  end-page: 79
  ident: BIB5
  article-title: Investigation on bonding and disintegration properties of pharmaceutical materials
  publication-title: Int. J. Pharm.
– volume: 75
  start-page: 271
  year: 1986
  end-page: 274
  ident: BIB9
  article-title: Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans
  publication-title: J. Pharm. Sci.
– volume: 63
  start-page: 136
  year: 1974
  end-page: 137
  ident: BIB17
  article-title: CMC of polysorbates
  publication-title: J. Pharm. Sci.
– volume: 7
  start-page: 1026
  year: 1990
  end-page: 1032
  ident: BIB1
  article-title: Application of radio telemetric technique in evaluating diclofenac sodium absorption after oral administration of various dosage forms in healthy volunteers
  publication-title: Pharm. Res.
– volume: 7
  start-page: 656
  year: 1984
  ident: 10.1016/S0378-5173(00)00552-4_BIB12
  article-title: Development and evaluation of a new peroral test agent GA-test for assessment of gastric acidity
  publication-title: J. Pharm. Dyn.
  doi: 10.1248/bpb1978.7.656
– volume: 69
  start-page: 649
  year: 1975
  ident: 10.1016/S0378-5173(00)00552-4_BIB16
  article-title: Gastric emptying and its relationship to antral contractile activity
  publication-title: Gastroenterogy
  doi: 10.1016/S0016-5085(19)32458-8
– volume: 8
  start-page: 1281
  year: 1991
  ident: 10.1016/S0378-5173(00)00552-4_BIB2
  article-title: Correlation of the gastric emptying of non-disintegrating tablets with gastrointestinal motility
  publication-title: Pharm. Res.
  doi: 10.1023/A:1015855829864
– volume: 22
  start-page: 571
  year: 1986
  ident: 10.1016/S0378-5173(00)00552-4_BIB15
  article-title: Food induced changes in theophylline absorption from a once a day theophylline project
  publication-title: Br. J. Clin. Pharmac.
  doi: 10.1111/j.1365-2125.1986.tb02937.x
– volume: 112
  start-page: 207
  year: 1994
  ident: 10.1016/S0378-5173(00)00552-4_BIB7
  article-title: The effect of food on the in vivo behaviour of enteric coated starch capsules
  publication-title: Int. J. Pharm.
  doi: 10.1016/0378-5173(94)90356-5
– volume: 7
  start-page: 1026
  year: 1990
  ident: 10.1016/S0378-5173(00)00552-4_BIB1
  article-title: Application of radio telemetric technique in evaluating diclofenac sodium absorption after oral administration of various dosage forms in healthy volunteers
  publication-title: Pharm. Res.
  doi: 10.1023/A:1015987016003
– volume: 75
  start-page: 271
  year: 1986
  ident: 10.1016/S0378-5173(00)00552-4_BIB9
  article-title: Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.2600750313
– volume: 55
  start-page: 285
  year: 1966
  ident: 10.1016/S0378-5173(00)00552-4_BIB8
  article-title: Factors affecting the absorption of riboflavin in man
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.2600550305
– volume: 12
  start-page: 237
  year: 1995
  ident: 10.1016/S0378-5173(00)00552-4_BIB6
  article-title: Estimation of agitation intensity in the GI tract in humans and dogs based on in vitro/in vivo correlation
  publication-title: Pharm. Res.
  doi: 10.1023/A:1016231010301
– volume: 8
  start-page: 97
  year: 1991
  ident: 10.1016/S0378-5173(00)00552-4_BIB11
  article-title: Mechanism of gastric emptying of a non-disintegrating radiotelemetry capsule in man
  publication-title: Pharm. Res.
  doi: 10.1023/A:1015894626403
– volume: 63
  start-page: 136
  year: 1974
  ident: 10.1016/S0378-5173(00)00552-4_BIB17
  article-title: CMC of polysorbates
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.2600630136
– volume: 40
  start-page: 205
  year: 1988
  ident: 10.1016/S0378-5173(00)00552-4_BIB4
  article-title: Gastric emptying of large single unit dosage forms
  publication-title: J. Pharm. Pharmacol.
  doi: 10.1111/j.2042-7158.1988.tb05220.x
– volume: 136
  start-page: 71
  year: 1996
  ident: 10.1016/S0378-5173(00)00552-4_BIB5
  article-title: Investigation on bonding and disintegration properties of pharmaceutical materials
  publication-title: Int. J. Pharm.
  doi: 10.1016/0378-5173(96)04489-4
– volume: 27
  start-page: 886
  year: 1986
  ident: 10.1016/S0378-5173(00)00552-4_BIB3
  article-title: Transit of pharmaceutical dosage forms through the small intestine
  publication-title: Gut
  doi: 10.1136/gut.27.8.886
– volume: 76
  start-page: 801
  year: 1979
  ident: 10.1016/S0378-5173(00)00552-4_BIB10
  article-title: Sieving of solid food by the canine stomach and sieving after gastric surgery
  publication-title: Gastroenterology
  doi: 10.1016/S0016-5085(79)80182-1
– volume: 12
  start-page: 1049
  year: 1995
  ident: 10.1016/S0378-5173(00)00552-4_BIB13
  article-title: Oral solid controlled release dosage forms: role of GI-mechanical destructive forces and colonic release in drug absorption under fasting and fed conditions in humans
  publication-title: Pharm. Res.
  doi: 10.1023/A:1016270701021
– volume: 24
  start-page: 790
  year: 1983
  ident: 10.1016/S0378-5173(00)00552-4_BIB14
  article-title: Gastric manometric abnormalities in patients with dyspeptic symptoms after fundoplication
  publication-title: Gut
  doi: 10.1136/gut.24.9.790
SSID ssj0006213
Score 2.0039904
Snippet The purpose of this study was to prepare tablets that could evaluate the destructive force in the gastrointestinal (GI) tract. Many factors are known to affect...
SourceID proquest
pubmed
pascalfrancis
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 61
SubjectTerms Adult
Biological and medical sciences
Biomechanical Phenomena
Compressive Strength
Destructive force
Fasting - urine
Gastrointestinal Contents
Gastrointestinal Motility - physiology
Gastrointestinal transit
General pharmacology
Humans
Male
Medical sciences
Middle Aged
Particle Size
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Photosensitizing Agents - chemistry
Photosensitizing Agents - urine
Polytetrafluoroethylene - chemistry
Polytetrafluoroethylene - pharmacokinetics
Powders
Riboflavin
Riboflavin - chemistry
Riboflavin - urine
Solubility
Stomach
Tablets
Teflon
Title A unique dosage form to evaluate the mechanical destructive force in the gastrointestinal tract
URI https://dx.doi.org/10.1016/S0378-5173(00)00552-4
https://www.ncbi.nlm.nih.gov/pubmed/11064212
https://www.proquest.com/docview/72390258
Volume 208
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBZ5XAqhNEmbbpuHDiG0EGdlSbbXxyUkbFsaAk0gN6FnWGjthd0t5NLf3hlZG5NDCORqa2RZM5r5ZGu-IeS4qiDsCxOyKtc2k1b7zBhrMqeFL21tdMgxUfjnVTm5ld_virs1cr7KhcFjlcn3dz49eut0ZZhmczibToe_mIiF5QW63KLgcp1sclGXYNqb428_JlePDrnkqUoybJhQoE_k6TqJF78w9jX2k8nnQtTWTM9h4kJX8eJ5SBpD0-U78jZhSjruhr1N1nyzQ06uO1Lqh1N60-dYzU_pCb3u6aofdoka02VkcaWuxVNmFGEsXbQ0EYF7ChiR_vGYIowapc4n0tm_sa31dNrENvcabrRIQAF-A0e0wBSs9-T28uLmfJKlsguZFTVbZDWzkVXOFcGWIgAgAZ3VllfBFYI5W9U6d6UfOa6FrC0y2HATPGwUvTGCe_GBbDRt4z8S6oXmgelQ5bmTxjkDaDE46EIbZrQYDYhczbSyiZMcS2P8Vv3hM1CQQgUphkSmoCAlB-TsUWzWkXK8JDBaqVE9sS4FgeMl0YMnau8fWCA0zgfkaGUGClYm_m7RjW-Xc1WBNQKihJfc66yjF81jfjH_9PphfSZvIikAfuCW-2QD9O4PAB4tzCFZP_uXH6ZF8B86QAtf
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dSxwxEA9WH1ooRft59SsPRVpwvWyS3b19FFFOqyL0BN9CPstBu3twZ8GX_u3OZHMuPojgazaTzWY-MtnM_IaQb1UF274wIatybTNptc-MsSZzWvjS1kaHHBOFLy7L8bU8uyluVsjRMhcGwyqT7e9serTWqWWYVnM4m06Hv5iIheUFmtyi4PIVWZOgvqidB__7OI-SpxrJcFzC7n0aTzdEbPzO2I84Siaf2qDezvQcli109S6edkjjxnSyTt4lj5IedpPeICu-eU_2rjpI6rt9OukzrOb7dI9e9WDVdx-IOqS3EcOVuhZjzCg6sXTR0gQD7il4iPSvxwRh5Cd1PkHO_ot9rafTJvb5reFBi_ATYDVwRgtMwPpIrk-OJ0fjLBVdyKyo2SKrmY2Ycq4IthQB3BHgWG15FVwhmLNVrXNX-pHjWsjaIn4NN8HDMdEbI7gXn8hq0zb-C6FeaB6YDlWeO2mcM-ArBgdDaMOMFqMBkcuVVjYhkmNhjD-qDz0DBilkkGIIYwoMUnJADh7IZh0kx3MEoyUb1SPZUrBtPEe6_Yjt_QsLdIzzAdldioECvcTLFt349nauKi7wBhc-8nMnHT1pHrOL-deXT2uXvB5PLs7V-enlz03yJsID4K9uuUVWQQb8NjhKC7MTFeEeYlcMIw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+unique+dosage+form+to+evaluate+the+mechanical+destructive+force+in+the+gastrointestinal+tract&rft.jtitle=International+journal+of+pharmaceutics&rft.au=Kamba%2C+Masaharu&rft.au=Seta%2C+Yasuo&rft.au=Kusai%2C+Akira&rft.au=Ikeda%2C+Masaru&rft.date=2000-11-04&rft.pub=Elsevier+B.V&rft.issn=0378-5173&rft.eissn=1873-3476&rft.volume=208&rft.issue=1&rft.spage=61&rft.epage=70&rft_id=info:doi/10.1016%2FS0378-5173%2800%2900552-4&rft.externalDocID=S0378517300005524
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0378-5173&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0378-5173&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0378-5173&client=summon